116 million yuan!

The "sorrows and joys" between pharmaceutical companies are not the same

Some companies are experiencing layoffs and delistings, while others are reaching new highs in performance and valuation

Moderna, which has made a name for itself in the new crown epidemic, its CEO has doubled his salary in two years and increased his salary by 41% in one year.

Obviously, the CEO's salary is closely related to the company's performance as the helm of the company

01.

The global pandemic of the new crown epidemic has made Moderna, a vaccine research and development company, a household name

Bancel's salary consists of the following components: a base salary of $1 million, a commission of $1.

In the past year, Moderna's market value once exceeded 200 billion US dollars, and its performance also hit a new high.

In addition, other executives at Moderna saw their total revenue grow substantially last year

Moderna President Stephen Hoge's total compensation for 2021 is $7.

In stark contrast to the big pay rises generally seen by executives, the median annual salary for Moderna's rank-and-file employees fell by 16%

In this regard, Moderna said that the decline in the median salary of ordinary employees was mainly caused by the increase in hired employees

02.

GSK CEO Emma Walmsley's earnings in 2021 have also been boosted along with GSK's performance

GSK achieved £34.

The increase in performance has brought Emma Walmsley's annual salary to 8.

Compensation for other executives also increased slightly
.
Outgoing GSK president and head of research and development Hal Barron received $12.
5 million in compensation last year, an increase from $11.
2 million in 2020
.
GSK CFO Ian McKay's salary has risen from £2m to £5.
3m, much of it thanks to his first profit-sharing scheme award since joining GSK in 2019, which saw his compensation pay An increase of £2.
4 million
.

In addition, GSK said Moncef Slaoui agreed to return $3.
86 million in cash under the company's "takeback policy
.
" It is reported that Slaoui has resigned as chairman of Galvani Bioelectronics' board of directors, and he resigned over sexual harassment allegations when he was the head of the vaccine unit
.

In its annual report, GSK said, "Overall, 2021 is a year of strong sales performance for GSK, well-developed strategy, and significant progress in innovation, the biopharmaceutical R&D pipeline
.
" At the same time, GSK is undergoing reforms, the The company is spinning off its consumer health business through a spinoff and creating a new independent company, Haleon, which will go public in the middle of this year
.

03.
Roche & Novartis: Missed the TOP 15 salary in the third year?

Judging from the statistics of CEO compensation of global pharmaceutical giants in recent years, it is a common law in recent years that CEOs of pharmaceutical companies from Europe are paid less than CEOs of US pharmaceutical companies
.
Two Swiss companies, Roche and Novartis, have missed out on the top 15 CEO salaries of global pharmaceutical giants for two consecutive years
.

Although Roche and Novartis are among the top five drugmakers in the world by 2021 revenue, the CEOs of both companies are not typically among the highest paid in the industry
.
Looking at annual CEO salaries in 2021, the CEOs of both companies are making just over $12 million
.

Roche CEO Severin Schwan's total compensation last year was 11.
49 million Swiss francs (about 12.
58 million US dollars)
.
From the salary structure, its annual salary is 4 million Swiss francs, and bonuses worth 8 million Swiss francs
.
In addition, Schwan received share appreciation rights worth CHF 3.
38 million and restricted stock units worth nearly CHF 600,000, which, when combined with other compensation such as pension funds and reimbursement allowances, brings his total compensation to CHF 11.
49 million
.
For Schwan, his payroll is up 4% in 2021
.

Novartis CEO Vas Narasimhan received compensation worth 11.
22 million Swiss francs ($12.
28 million) in his fourth year as CEO of the company
.
Vas Narasimhan's compensation structure is as follows: about CHF 2.
2 million comes from fixed compensation and benefits, and the remaining CHF 9 million comes from its performance-based compensation plan
.

Novartis said the payout came after the company achieved several long-term goals set by Narasimhan
.
Specifically, Novartis' annual growth target reached 119% of Narasimhan's long-term performance plan target, and Novartis' core operating income growth was twice the CEO's target
.
Novartis said it also exceeded the performance plan targets set by the CEO in terms of innovation metrics
.

For Narasimhan, the compensation of 11.
22 million Swiss francs is an 8% increase from his 2020 salary of 10.
38 million Swiss francs
.

However, the annual salary of Schwan and Narasimhan is about 12 million US dollars.
Perhaps the CEOs of Roche and Novartis will again be absent from the ranks of the annual TOP15 this year
.

04.
AZ: below $20 million

AstraZeneca CEO Pascal Soriot, who received an annual salary of 15.
45 million pounds (about 21.
52 million U.
S.
dollars) last year, will receive an annual income of 13.
86 million pounds (about 19.
08 million U.
S.
dollars) in 2021
.
Judging from the salary structure of Pascal Soriot, the basic salary is 1.
32 million pounds, the benefits are 123,000 pounds, the pension is 146,000 pounds, the bonus is 3.
15 million pounds and the long-term reward is 9 million pounds
.

AstraZeneca said in its annual report: "2021 is a 'truly special year' for Soriot at the helm of AstraZeneca.
Soriot has fully demonstrated its leadership in the ongoing COVID-19 pandemic, and Soriot has helped the company become the first Drugmakers that have signed up to the Global Vaccine Distribution Program have now deployed more than 2.
5 billion doses of vaccine globally, generating revenue of $3.
98 billion
.
"

Under Soriot's leadership, AstraZeneca has narrowed its commercial and R&D operations to three main areas: Oncology, Respiratory, Cardiovascular & Renal and Metabolic
.
More specifically, AstraZeneca's product pipeline is also skewed toward cancer, with 97 of its 164 clinical research programs in this area
.

In terms of performance, AstraZeneca's total revenue in 2021 is US$37.
417 billion, a year-on-year increase of 41%
.
For Soriot, however, whether he can achieve $40 billion in annual sales by 2023 will be a big question ahead of him, a goal he set in 2014
.

Note:

1.
The list of multinational pharmaceutical companies presented in this article is a company that can publicly query the annual salary data of executives as of the press release.
More multinational pharmaceutical companies executive compensation data E-drug managers will continue to pay attention in the future

2.
The exchange rate involved in the article: 1 Swiss franc = 1.
0946 US dollars; 1 British pound = 1.
3764 US dollars; 1 US dollar = 6.
3757 RMB (the exchange rate is calculated based on the average exchange rate in 2021)

Original link: https:// href="https://" target="_blank">https://